Skip to main content

Phenacemide Disease Interactions

There are 2 disease interactions with phenacemide.

Moderate

Antiepileptics (applies to phenacemide) suicidal tendency

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Depression, Psychosis

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. AEDs should be administered cautiously in patients with depression or other psychiatric disorders; phentermine-topiramate should be avoided in patients with history of suicidal attempts or active suicidal ideation. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.

References

  1. "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals PROD (2002):
  2. "Product Information. Klonopin (clonazepam)." Roche Laboratories PROD (2001):
  3. "Product Information. Dilantin (phenytoin)." Parke-Davis PROD (2001):
  4. "Product Information. Cerebyx (fosphenytoin)." Parke-Davis PROD (2001):
  5. "Product Information. Mysoline (primidone)." Elan Pharmaceuticals PROD (2001):
  6. "Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group (2005):
  7. "Product Information. Sabril (vigabatrin)." Lundbeck Inc (2009):
  8. "Product Information. Potiga (ezogabine)." GlaxoSmithKline (2011):
  9. "Product Information. Fycompa (perampanel)." Eisai Inc (2012):
  10. "Product Information. Briviact (brivaracetam)." UCB Pharma Inc (2016):
  11. "Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC (2018):
  12. "Product Information. Xcopri (cenobamate)." SK Life Science, Inc. (2020):
  13. "Product Information. Fintepla (fenfluramine)." Zogenix, Inc (2020):
  14. "Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc (2022):
  15. "Product Information. Diacomit (stiripentol)." Biocodex USA SUPPL-3 (2022):
  16. "Product Information. Qsymia (phentermine-topiramate)." Vivus Inc SUPPL-23 (2023):
  17. "Product Information. Topamax (topiramate)." Janssen Pharmaceuticals SUPPL-65 (2023):
View all 17 references
Moderate

Phenacemide (applies to phenacemide) renal dysfunction

Moderate Potential Hazard, High plausibility.

The use of phenacemide has occasionally been associated with nephritis characterized by marked albuminuria. Therapy with phenacemide should be administered cautiously in patients with preexisting renal dysfunction. Patients should have periodic urinalyses performed and phenacemide discontinued if marked albuminuria or other significant abnormalities are observed.

References

  1. "Product Information. Phenurone (phenacemide)." Abbott Pharmaceutical PROD (2001):

Phenacemide drug interactions

There are 229 drug interactions with phenacemide.

Phenacemide alcohol/food interactions

There is 1 alcohol/food interaction with phenacemide.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.